China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in ...

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, ...

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a ...

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

A 67-year-old man presented with multiorgan failure, hypoglycaemia, cholestatic liver dysfunction, and two duodenal ulcers ...

GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to an expert endocrine ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Through its LillyDirect pharmacy, Eli Lilly plans to offer steep discounts on single-dose vials of Zepbound by partnering ...

Eli Lilly and Company and Walmart Inc. announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound ...

Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE ...

Altimmune continues developing pemvidutide for MASH but has yet to secure a partner or acquisition despite sector M&A ...